Page 77 — вибір ад'ювантy вакцини та активація TLR-рецепторів вродженого імунітету: how danger-signal mimicry turns a weak antigen into a strong vaccine
A purified or recombinant vaccine antigen — a viral surface protein, a bacterial polysaccharide, a subunit fragment — presents the immune system with a molecular shape to recognize, but nothing else. Real infections arrive bundled with a flood of accompanying signals: microbial structural motifs, tissue damage, replicating nucleic acids. Stripped of that context, an isolated antigen frequently fails to generate a robust immune response, because it lacks the danger signals that naturally accompany real infections and alert the immune system to respond strongly.
Adaptive immunity depends on a two-signal model. Signal one is antigen recognition: a B-cell receptor or an antigen fragment presented on MHC to a T-cell. Signal two is costimulation, delivered by an antigen-presenting cell that has itself been activated. Without signal two, antigen recognition alone tends to produce tolerance or a weak, transient response rather than robust, durable immunity — the immune system's default assumption is that an unaccompanied molecule is harmless self-material, not a threat.
Purified subunit and recombinant protein antigens are deliberately minimal: they are engineered to present only the target epitope, stripped of the replicating genome, structural complexity, and metabolic byproducts that accompany a live pathogen. That purity is what makes them safe — but it is also precisely why, on their own, dendritic cells and macrophages sampling the injection site see little reason to mature, migrate to lymph nodes, or prime a strong T- and B-cell response.
This gap is the central rationale for adjuvants: reintroducing, in a controlled and safe way, the danger-signal context that a purified antigen cannot provide by itself.
Vaccine adjuvants are added specifically to solve the signal-two problem. From aluminum salts (alum, in use since the 1920s) to oil-in-water emulsions (MF59, AS03) to purified microbial components (monophosphoryl lipid A, CpG oligonucleotides), adjuvants provide danger-signal mimicry — activating innate immune pathways that boost the overall immune response to the co-administered antigen, without themselves causing disease.
Adjuvants work through several complementary mechanisms, often combined in a single formulation:
Depot effect: aluminum salts and oil-in-water emulsions slow antigen release at the injection site, prolonging exposure to immune cells and creating a local zone of inflammation that draws in monocytes and dendritic cells.
Direct innate-receptor engagement: many modern adjuvants are purified or synthetic molecules that structurally resemble pathogen-associated molecular patterns (PAMPs) — bacterial cell-wall lipids, viral RNA motifs, unmethylated bacterial DNA sequences. These are recognized directly by pattern-recognition receptors on innate immune cells.
Inflammasome activation: some particulate adjuvants (including alum) trigger the NLRP3 inflammasome, releasing IL-1β and IL-18 and reinforcing local inflammatory signaling.
The net effect across mechanisms is the same: the antigen is no longer presented in an immunologically "quiet" context. It arrives alongside a molecular signal that innate immune cells interpret as evidence of infection, prompting them to mature, upregulate costimulatory molecules, and prime a much stronger adaptive response.
Many adjuvants work by engaging toll-like receptors (TLRs) on innate immune cells — a family of pattern-recognition receptors that normally detect molecular signatures associated with pathogens. Monophosphoryl lipid A (a detoxified lipid A derivative) engages TLR4; CpG oligodeoxynucleotides engage TLR9 in endosomes; imidazoquinolines engage TLR7/8; poly I:C mimics viral double-stranded RNA and engages TLR3. Each receptor sits on a specific cell-surface or endosomal location and triggers a specific intracellular cascade.
Toll-like receptors are evolutionarily ancient sensors, present on and within dendritic cells, macrophages, and other innate cells. Each TLR is tuned to a distinct class of molecular pattern:
• Surface-expressed TLRs (TLR1, 2, 4, 5, 6) generally detect bacterial cell-wall and flagellar components. • Endosomal TLRs (TLR3, 7, 8, 9) detect nucleic-acid signatures — double-stranded RNA, single-stranded RNA, and unmethylated CpG-rich DNA respectively — patterns common in replicating pathogens but normally sequestered or methylated in host DNA.
Ligand binding triggers receptor dimerization and recruitment of intracellular adaptor proteins — chiefly MyD88 (used by nearly all TLRs except TLR3) or TRIF (used by TLR3 and, via an alternate route, TLR4). The adaptor used determines which downstream kinase cascade fires first, which is the molecular basis for why different adjuvants — even though all "activate innate immunity" — produce measurably different immune response profiles.
This is the mechanistic core of adjuvant design: choosing which TLR to engage is choosing which cascade, and therefore which flavor of immune response, gets switched on.
TLR engagement activates the innate immune cell: the MyD88/TRIF cascade converges on transcription factors including NF-κB and IRF3/7, driving transcription of pro-inflammatory cytokines and type I interferons. The activated cell matures — upregulating costimulatory molecules (CD80/CD86) and MHC — and releases signaling molecules that recruit and activate additional immune cells, amplifying the overall response to the vaccine well beyond what the antigen could trigger alone.
A single activated dendritic cell does not fight the vaccine's "battle" alone — it becomes a signaling hub. Cytokine release recruits monocytes and additional dendritic cells to the injection site, while the activated cell itself upregulates the chemokine receptor CCR7, migrates to the draining lymph node, and presents antigen fragments to naive T-cells alongside strong costimulatory signals.
This amplification cascade is why adjuvanted vaccines can achieve protective antibody titers and durable T-cell memory from a small antigen dose — the innate signal, not the antigen dose alone, is often the limiting factor for response magnitude. Illustrative modeling in this simulation reflects that relationship: response magnitude rises sharply once the TLR pathway is engaged, plateauing at a level shaped by how strongly and how broadly the activation cascade propagates through recruited cells.
Different adjuvants preferentially engage different TLRs and pathways, shaping not just the magnitude but the type — the qualitative character — of the resulting immune response. Alum tends to favor a Th2-skewed, antibody-heavy profile. TLR4 agonists such as MPLA favor a more balanced Th1/humoral response. TLR9 agonists such as CpG ODN drive strong Th1 polarization and robust CD8+ cytotoxic T-cell priming. Adjuvant choice is therefore a deliberate design decision, informed by the specific immune response profile desired for a given vaccine.
Not every vaccine needs the same kind of immune response. A vaccine against an extracellular bacterial toxin may succeed primarily through neutralizing antibodies — favoring an adjuvant that skews Th2/humoral, such as alum. A vaccine against an intracellular pathogen, or one intended to protect against a virus that requires killing infected cells, benefits from strong Th1 polarization and cytotoxic CD8+ T-cell priming — favoring a TLR9 agonist such as CpG ODN, or a TLR4/TLR9 combination.
Modern licensed adjuvant systems increasingly combine multiple components deliberately for this reason: AS01 (monophosphoryl lipid A plus the saponin QS-21, used in the shingles vaccine Shingrix) engages complementary pathways to drive an unusually strong and durable cell-mediated response in an older population with declining baseline immunity. AS04 (MPL plus alum, used in some HPV and hepatitis B vaccines) balances antibody and cellular responses.
The practical takeaway: adjuvant selection is not a single "on/off" decision but a pathway-matching exercise — choosing the TLR(s) engaged, and therefore the resulting Th1/Th2/cytotoxic balance, to fit the biology of the specific pathogen and the protective correlate the vaccine is designed to achieve.
Because different TLR pathways produce measurably different immune response profiles, adjuvant selection is now treated as a core design variable in vaccine development — alongside antigen choice and dose — rather than as an inert booster added at the end of the process.